Takeda Pharmaceutical Company Ltd

Beacon Biosignals raised an oversubscribed $86 million Series B funding round to build the world's largest neurodiagnostic dataset and advance AI-driven biomarkers for brain health.

XOMA Royalty Corporation reported robust financial performance in Q3 2025, receiving $43.9 million in royalties and milestones from partners in the first nine months of 2025, including $14.3 million in Q3 royalties.

Takeda's Phase 1b study demonstrates that mezagitamab (TAK-079) maintains stable kidney function in IgA nephropathy patients through Week 96, 18 months after the last dose.

Accipiter Biosciences has emerged from stealth with $12.7 million in seed financing co-led by Takeda and Flying Fish Partners to develop de novo multifunctional biologics for complex diseases.

VOQUEZNA (vonoprazan) demonstrated significant improvement in nocturnal GERD symptoms in patients with Non-Erosive Reflux Disease, with 59.9% and 56.4% heartburn-free nights for 10mg and 20mg doses respectively versus 43.3% for placebo.

Abeona Therapeutics has appointed James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately.

Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.

Ultragenyx Pharmaceutical appointed Eric Olson as Chief Business Officer and Executive Vice President effective September 22, 2025, following Thomas Kassberg's planned retirement after 14 years with the company.

Crystalys Therapeutics launched with $205 million in Series A funding to develop dotinurad, a URAT1 blocker for gout treatment that is already approved in Japan, China, Philippines, and Thailand.

Star Therapeutics raised $125 million in Series D funding co-led by Sanofi Ventures and Viking Global Investors to advance its Von Willebrand disease drug VGA039 through late-stage clinical testing.